

**Supplemental Table 4: Study eye serious adverse events up to 200 days post-dose, with outcomes, by treatment group**

Preferred term	Control				Ocriclasmin			
	All n (%) <sup>a</sup>	Recovered n (%) <sup>b</sup>	Sequelae n (%) <sup>b</sup>	Ongoing n (%) <sup>b</sup>	All n (%) <sup>c</sup>	Recovered n (%) <sup>d</sup>	Sequelae n (%) <sup>d</sup>	Ongoing n (%) <sup>d</sup>
Macular hole progression	17 (17.3)	14 (82.4)	2 (11.8)	1 (5.9)	45 (22.5)	37 (82.2)	3 (6.7)	5 (11.1)
New macular hole	8 (3.4)	7 (87.5)		1 (12.5)	8 (1.5)	5 (62.5)		3 (37.5)
Retinal detachment	4 (1.2)	3 (75.0)	1 (25.0)		6 (0.8)	4 (66.7)		2 (33.3)
Vitreous adhesions	4 (1.2)	3 (75.0)	1 (25.0)		5 (0.7)	4 (80.0)	1 (20.0)	
Maculopathy	0 (0.0)				3 (0.4)	3 (100.0)		
Visual acuity reduced	2 (0.6)	2 (100.0)			3 (0.4)	1 (33.3)	1 (33.3)	1 (33.3)
Intraocular pressure increased	2 (0.6)	2 (100.0)			3 (0.4)	3 (100.0)		
Retinal vasculitis	0 (0.0)				1 (0.1)	1 (100.0)		
Night blindness	0 (0.0)				1 (0.1)	1 (100.0)		
Retinal tear	1 (0.3)	1 (100.0)			1 (0.1)	1 (100.0)		
Retinal toxicity	0 (0.0)				1 (0.1)			1 (100.0)
Pupillary reflex impaired	0 (0.0)				1 (0.1)	1 (100.0)		
Blindness transient	0 (0.0)				1 (0.1)	1 (100.0)		
Ocular hypertension	0 (0.0)				1 (0.1)	1 (100.0)		
Retinogram abnormal	0 (0.0)				1 (0.1)	1 (100.0)		
Vitreous haemorrhage	0 (0.0)				1 (0.1)		1 (100.0)	
Eye inflammation	0 (0.0)				1 (0.1)	1 (100.0)		
Hyphaema	0 (0.0)				1 (0.1)	1 (100.0)		
Angle closure glaucoma	0 (0.0)				1 (0.1)	1 (100.0)		
Posterior capsule opacification	0 (0.0)				1 (0.1)			1 (100.0)
Macular pseudohole	0 (0.0)				1 (0.1)	1 (100.0)		

<sup>a</sup>Control group denominator is 330, except for macular hole progression (98) and new macular hole (232).

<sup>b</sup>Denominator is the number of control group serious adverse events in the corresponding preferred term.

<sup>c</sup>Ocriclasmin denominator is 737, except for macular hole progression (200) and new macular hole (537).

<sup>d</sup>Denominator is the number of ocriclasmin serious adverse events in the corresponding preferred term.